Beta (β)-lactam antibiotic is an industrially important molecule produced by Penicillium chrysogenum/rubens. Penicillin is a building block for 6-aminopenicillanic acid (6-APA), an important active pharmaceutical intermediate (API) used for semi-synthetic antibiotics biosynthesis. In this investigation, we isolated and identified Penicillium chrysogenum, P. rubens, P. brocae, P. citrinum, Aspergillus fumigatus, A. sydowii, Talaromyces tratensis, Scopulariopsis brevicaulis, P. oxalicum, and P. dipodomyicola using the internal transcribed spacer (ITS) region and the β-tubulin (BenA) gene for precise species identification from Indian origin. Furthermore, the BenA gene distinguished between complex species of P. chrysogenum and P. rubens to a certain extent which partially failed by the ITS region. In addition, these species were distinguished by metabolic markers profiled by liquid chromatography–high resolution mass spectrometry (LC-HRMS). Secalonic acid, Meleagrin, and Roquefortine C were absent in P. rubens. The crude extract evaluated for PenV production by antibacterial activities by well diffusion method against Staphylococcus aureus NCIM-2079. A high-performance liquid chromatography (HPLC) method was developed for simultaneous detection of 6-APA, phenoxymethyl penicillin (PenV), and phenoxyacetic acid (POA). The pivotal objective was the development of an indigenous strain portfolio for PenV production. Here, a library of 80 strains of P. chrysogenum/rubens was screened for PenV production. Results showed 28 strains capable of producing PenV in a range from 10 to 120 mg/L when 80 strains were screened for its production. In addition, fermentation parameters, precursor concentration, incubation period, inoculum size, pH, and temperature were monitored for the improved PenV production using promising P. rubens strain BIONCL P45. In conclusion, P. chrysogenum/rubens strains can be explored for the industrial-scale PenV production.

Fusarium verticillioides is a plant pathogenic fungus affecting a wide range of crops worldwide due to its toxigenic properties. F. verticillioides BIONCL4 strain was isolated from stored maize grain samples in India, and produces high amount of fumonisin B1 (FB1). We report a comparative genomic analysis of F. verticillioides, covering the basic genome information, secretome, and proteins involved in host–pathogen interactions and mycotoxin biosynthesis. Whole-genome sequencing (WGS) was performed using the Illumina platform with an assembly size of 42.91 Mb, GC content of 48.24%, and 98.50% coverage with the reference genome (GCA000149555). It encodes 15,053 proteins, including 2058 secretory proteins, 676 classical secretory proteins, and 569 virulence and pathogenicity-related proteins. There were also 1447 genes linked to carbohydrate active enzymes (CaZymes) and 167 genes related to mycotoxin production. Furthermore, F. verticillioides genome comparison revealed information about the species’ evolutionary history. The overall study helps in disease prevention and management of mycotoxins to ensure food safety.

Biomanufacturing relies on microorganisms as production platforms due to their inherent metabolic versatility, rapid growth, and suitability for scalable biological processes. Compared to plant and mammalian systems, microbial platforms are preferred because they enable efficient process control, flexible substrate utilization, and straightforward translation from laboratory to industrial scale. Central to the success of microbial biomanufacturing is strain engineering, which allows the redirection of metabolic fluxes, enhancement of product yields, and improvement of robustness under industrial operating conditions. Despite advances in molecular and systems level tools, strain improvement remains a major bottleneck, particularly when transitioning from proof-of-concept to large-scale production. Additional challenges include process scale-up, infrastructure availability, regulatory harmonization, and workforce capacity. In the Indian context, national initiatives such as Make in India and the BioE3 policy are supporting the development of domestic biomanufacturing capabilities, however, continued dependence on imported single-use components and high capital and operational costs limit broader adoption. Future progress is expected to be driven by systematic strain engineering, data-driven design–build-test cycles, and integrated biofoundry models, enabling the establishment of a resilient and competitive biomanufacturing ecosystem.